abrdn Life Sciences Investors
HQL
$18.44
-$0.30-1.60%
| Weiss Ratings | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Reward Grade | C | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Company Info | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Provider | abrdn Inc. | |||
| Manager/Tenure (Years) | Jason C. Akus (2) | |||
| Website | http://www.abrdn.com/us | |||
| Fund Information | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Fund Name | abrdn Life Sciences Investors | |||
| Category | Health | |||
| Sub-Category | Healthcare Sector Equity | |||
| Prospectus Objective | Specialty - Health | |||
| Inception Date | May 08, 1992 | |||
| Open/Closed To New Investors | Open | |||
| Minimum Initial Investment | -- | |||
| Minimum Subsequent Investment | -- | |||
| Front End Fee | -- | |||
| Back End Fee | -- | |||
| Dividends and Shares | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield | 2.79% | |||
| Dividend | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield (Forward) | 0.03% | |||
| Asset Allocation | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash | 2.27% | |||
| Stock | 90.37% | |||
| U.S. Stock | 82.86% | |||
| Non-U.S. Stock | 7.51% | |||
| Bond | 0.00% | |||
| U.S. Bond | 0.00% | |||
| Non-U.S. Bond | 0.00% | |||
| Preferred | 5.55% | |||
| Convertible | 0.07% | |||
| Other Net | 1.75% | |||
| Price History | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.90% | |||
| 30-Day Total Return | -4.58% | |||
| 60-Day Total Return | -14.77% | |||
| 90-Day Total Return | -9.78% | |||
| Year to Date Total Return | 10.81% | |||
| 1-Year Total Return | 8.40% | |||
| 2-Year Total Return | 44.73% | |||
| 3-Year Total Return | 85.52% | |||
| 5-Year Total Return | 48.82% | |||
| Price | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Closing Price | -- | |||
| 1-Month Low Price | $16.78 | |||
| 1-Month High Price | $18.74 | |||
| 52-Week Low Price | $15.87 | |||
| 52-Week Low Price (Date) | Mar 06, 2026 | |||
| 52-Week High Price | $22.67 | |||
| 52-Week High Price (Date) | Aug 19, 2026 | |||
| NAV | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Nav | $19.16 | |||
| 1-Month Low NAV | $17.44 | |||
| 1-Month High NAV | $19.85 | |||
| 52-Week Low NAV | $17.41 | |||
| 52-Week Low NAV (Date) | Mar 30, 2026 | |||
| 52-Week High NAV | $23.77 | |||
| 52-Week High Price (Date) | Aug 19, 2026 | |||
| Beta / Standard Deviation | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.94 | |||
| Standard Deviation | 19.98 | |||
| Balance Sheet | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Total Assets | 621.49M | |||
| Operating Ratios | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Expense Ratio | 1.35% | |||
| Turnover Ratio | 73.00% | |||
| Performance | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Last Bull Market Total Return | 45.72% | |||
| Last Bear Market Total Return | -8.89% | |||